CBIO Q1 2024 Earnings — Crescent Biopharma, Inc. Revenue & Financial Results | Market Cap Arena

CBIOCrescent Biopharma, Inc.

$345M

Q1 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

-$14,620

Operating Income

-$11M

Net Income

-$11M

EPS (Diluted)

$-0.17

QoQ Revenue Growth

-100.0%

Cash Flow

Operating Cash Flow

-$11M

Free Cash Flow

-$11M

Stock-Based Comp.

$1M

Balance Sheet

Total Assets

$34M

Total Liabilities

$5M

Stockholders' Equity

$29M

Cash & Equivalents

$31M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	-$14,620	-$262,958	+94.4%
Operating Income	-$11M	-$11M	-1.6%
Net Income	-$11M	-$10M	-3.6%